Cancer clinical trials in the region Pays de la Loire

219 currently recruiting clinical trials
Region Pays de la Loire

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
Phase 3 Lung cancer
#NCT06635824
NSCLC (Non-Small Cell Lung Cancer) Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) 1 2 Immunotherapy Chemotherapy
ALK BRAF EGFR KRAS G12C KRAS non G12C MET RET ROS-1 Systemic Treatment-Naive Car-T
Hôpital Privé du Confluent - Vivalto Santé (Nantes), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Hospitalier Universitaire Angers (Angers )
Genmab
Phase 3 Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Systemic Treatment-Naive
Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Nantes (Nantes), Hôpital Privé du Confluent - Vivalto Santé (Nantes)
Daiichi Sankyo
Phase 3 Lymphoma
#NCT05947851
B cell lymphoma Lymphocytic lymphoma None Treated / Controled 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon)
Merck Sharp & Dohme LLC
Phase 3 CLL & Richter's syndrome
#NCT05947851
CLL (Chronic Lymphocytic Leukemia) None Treated / Controled 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon)
Merck Sharp & Dohme LLC
Phase 3 Prostate cancer
#NCT06764485
Adenocarcinoma Metastatic Castration-resistant 1 2 3 or more Hormone therapy
Systemic Treatment-Naive
Clinique Victor Hugo - Elsan (Le Mans)
Celgene